LGND vs XNCR
LGND: Ligand Pharmaceuticals is a high-margin, asset-light biopharmaceutical firm that earns royalties and milestone payments from a diverse portfolio of licensed drug development programs and its proprietary Captisol formulation technology. XNCR: A clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines using its proprietary protein engineering platforms to treat cancer and autoimmune diseases.
Side-by-side fundamentals
| Metric | LGND | XNCR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $295.00 | $24.50 | |
| Market cap | $5.9B | $1.8B | |
| P/E as of 2026-10-08 | 39.74 | n/a | |
| Net margin FY2025, SEC XBRL | +46.4% | -73.2% | LGND higher |
| Operating margin FY2025, SEC XBRL | +15.3% | -141.4% | LGND higher |
| ROE FY2025, SEC XBRL | +12.2% | -14.5% | LGND higher |
| ROA FY2025, SEC XBRL | +8.0% | -10.5% | LGND higher |
| Debt / equity as of 2026-09-03 | 0.45 | 0.21 | XNCR lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | -33.2% | |
| Revenue CAGR (3y) SEC XBRL | +11.0% | -8.6% | LGND higher |
| Dividend streak (yrs) SEC XBRL | 1 | 0 | LGND higher |
| Beta as of 2026-09-03 | 0.96 | 1.38 | |
| 1-year return as of 2026-10-08 close | +59.9% | +97.6% | XNCR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.